Prognostic relevance of treatment response measured by flow cytometric residual disease detection in older patients with acute myeloid leukemia.

PURPOSE Older patients with acute myeloid leukemia (AML) have a high relapse rate after standard chemotherapy. We investigated whether measuring chemotherapy sensitivity by multiparameter flow cytometric minimal residual disease (MFC-MRD) detection has prognostic value in patients older than age 60 years or is simply a surrogate for known age-related risk factors. PATIENT AND METHODS Eight hundred ninety-two unselected patients treated intensively in the United Kingdom National Cancer Research Institute AML16 Trial were assessed prospectively for MFC-MRD during treatment. Eight hundred thirty-three patients had leukemia-associated immunophenotypes (LAIPs) identified by pretreatment screening. Four hundred twenty-seven patients entered complete remission (CR) after one or two courses (designated C1 and C2, respectively) and were MFC-MRD assessable by LAIP detection in CR bone marrow for at least one of these time points. MRD positivity was defined as residual disease detectable by LAIP. RESULTS MFC-MRD negativity, which was achieved in 51% of patients after C1 (n = 286) and 64% of patients after C2 (n = 279), conferred significantly better 3-year survival from CR (C1: 42% v 26% in MRD-positive patients, P < .001; C2: 38% v 18%, respectively; P < .001) and reduced relapse (C1: 71% v 83% in MRD-positive patients, P < .001; C2: 79% v 91%, respectively; P < .001), with higher risk of early relapse in MRD-positive patients (median time to relapse, 8.5 v 17.1 months, respectively). In multivariable analysis, MRD status at the post-C1 time point independently predicted survival, identifying a subgroup of intermediate-risk patients with particularly poor outcome. However, survival benefit from gemtuzumab ozogamicin was not associated with MFC-MRD chemotherapy sensitivity. CONCLUSION Early assessment of treatment response using flow cytometry provides powerful independent prognostic information in older adults with AML, lending support to the incorporation of MRD detection to refine risk stratification and inform clinical trial design in this challenging group of patients.

[1]  John M. Ashton,et al.  BCL-2 inhibition targets oxidative phosphorylation and selectively eradicates quiescent human leukemia stem cells. , 2013, Cell stem cell.

[2]  E. Paietta,et al.  Minimal residual disease in acute myeloid leukemia: coming of age. , 2012, Hematology. American Society of Hematology. Education Program.

[3]  Elaine Coustan-Smith,et al.  Comparative analysis of different approaches to measure treatment response in acute myeloid leukemia. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  P. Hokland,et al.  Sensitivity of minimal residual disease in acute myeloid leukaemia in first remission – methodologies in relation to their clinical situation , 2012, British journal of haematology.

[5]  Todd A Alonzo,et al.  Residual disease detected by multidimensional flow cytometry signifies high relapse risk in patients with de novo acute myeloid leukemia: a report from Children's Oncology Group. , 2012, Blood.

[6]  C. Craddock,et al.  Addition of gemtuzumab ozogamicin to induction chemotherapy improves survival in older patients with acute myeloid leukemia. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  Sean C. Bendall,et al.  From single cells to deep phenotypes in cancer , 2012, Nature Biotechnology.

[8]  I. Bernstein,et al.  Acute myeloid leukemia stem cells and CD33-targeted immunotherapy. , 2012, Blood.

[9]  N. Socci,et al.  Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. , 2012, The New England journal of medicine.

[10]  L. Godley.  Profiles in leukemia. , 2012, The New England journal of medicine.

[11]  G. Nolan,et al.  Decoupling of tumor-initiating activity from stable immunophenotype in HoxA9-Meis1-driven AML. , 2012, Cell stem cell.

[12]  Y. Assaraf,et al.  The role of minor subpopulations within the leukemic blast compartment of AML patients at initial diagnosis in the development of relapse , 2012, Leukemia.

[13]  F. Lo‐Coco,et al.  Prognostic and therapeutic implications of minimal residual disease detection in acute myeloid leukemia. , 2012, Blood.

[14]  R. Hills,et al.  Minimal residual disease monitoring by quantitative RT-PCR in core binding factor AML allows risk stratification and predicts relapse: results of the United Kingdom MRC AML-15 trial. , 2007, Blood.

[15]  E. Estey,et al.  Prediction of early death after induction therapy for newly diagnosed acute myeloid leukemia with pretreatment risk scores: a novel paradigm for treatment assignment. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  W. Hiddemann,et al.  Front Line Treatment of Elderly Patients with Acute Promyelocytic Leukemia: Long-Term Results of the German AML Cooperative Group , 2011 .

[17]  W. Hiddemann,et al.  A Combined Score of Minimal Residual Disease (MRD) Assessment by Flow Cytometry, Cytogenetic and Molecular Markers As Well As Age Predicts Outcome and Can Potentially Guide MRD-Based Therapy in Acute Myeloid Leukemia , 2011 .

[18]  J. Godbold,et al.  The dominant negative β isoform of the glucocorticoid receptor is uniquely expressed in erythroid cells expanded from polycythemia vera patients. , 2011, Blood.

[19]  G. Schuurhuis,et al.  Review of the relevance of aberrant antigen expression by flow cytometry in myeloid neoplasms , 2011, British journal of haematology.

[20]  P. Hokland,et al.  Towards individualized follow-up in adult acute myeloid leukemia in remission. , 2011, Blood.

[21]  R. Hills,et al.  Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML15 trial. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  B. Löwenberg,et al.  Therapeutic advances in acute myeloid leukemia. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  W. Hiddemann,et al.  Complete remission and early death after intensive chemotherapy in patients aged 60 years or older with acute myeloid leukaemia: a web-based application for prediction of outcomes , 2010, The Lancet.

[24]  P. Vyas,et al.  Assessment of minimal residual disease in acute myeloid leukemia , 2010, Current opinion in oncology.

[25]  J. Dongen,et al.  Clinical significance of flowcytometric minimal residual disease detection in pediatric acute myeloid leukemia patients treated according to the DCOG ANLL97/MRC AML12 protocol , 2010, Leukemia.

[26]  R. Hills,et al.  Prognostic significance of CEBPA mutations in a large cohort of younger adult patients with acute myeloid leukemia: impact of double CEBPA mutations and the interaction with FLT3 and NPM1 mutations. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  Elaine Coustan-Smith,et al.  Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: results of the AML02 multicentre trial. , 2010, The Lancet. Oncology.

[28]  G. Ossenkoppele,et al.  Aberrant immunophenotype of blasts in myelodysplastic syndromes is a clinically relevant biomarker in predicting response to growth factor treatment. , 2010, Blood.

[29]  M. Caligiuri,et al.  Favorable prognostic impact of NPM1 mutations in older patients with cytogenetically normal de novo acute myeloid leukemia and associated gene- and microRNA-expression signatures: a Cancer and Leukemia Group B study. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  Bob Löwenberg,et al.  Review Articles (434 articles) , 2008 .

[31]  S. Schnittger,et al.  Strikingly different molecular relapse kinetics in NPM1c, PML-RARA, RUNX1-RUNX1T1, and CBFB-MYH11 acute myeloid leukemias. , 2010, Blood.

[32]  Keith Wheatley,et al.  Prognostic factor analysis of the survival of elderly patients with AML in the MRC AML11 and LRF AML14 trials , 2009, British journal of haematology.

[33]  R. Hills,et al.  Independent Prognostic Factors for Aml Outcome Pre-treatment Prognostic Factors , 2022 .

[34]  F. Lo Coco,et al.  Toward optimization of postremission therapy for residual disease-positive patients with acute myeloid leukemia. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  D. Grimwade,et al.  Development of minimal residual disease-directed therapy in acute myeloid leukemia. , 2008, Seminars in oncology.

[36]  Axel Benner,et al.  Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. , 2008, The New England journal of medicine.

[37]  Adam J Mead,et al.  The impact of FLT3 internal tandem duplication mutant level, number, size, and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemia. , 2008, Blood.

[38]  T. Haferlach,et al.  Monitoring of minimal residual disease in acute myeloid leukemia , 2005, Cancer.

[39]  H. Kantarjian,et al.  The haematopoietic cell transplantation comorbidity index score is predictive of early death and survival in patients over 60 years of age receiving induction therapy for acute myeloid leukaemia. , 2007, British journal of haematology.

[40]  F. Lo‐Coco,et al.  The kinetics of reduction of minimal residual disease impacts on duration of response and survival of patients with acute myeloid leukemia , 2006, Leukemia.

[41]  Ursula Creutzig,et al.  Residual disease monitoring in childhood acute myeloid leukemia by multiparameter flow cytometry: the MRD-AML-BFM Study Group. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[42]  H. Gundacker,et al.  Age and acute myeloid leukemia. , 2006, Blood.

[43]  Susan O'Brien,et al.  Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high‐risk myelodysplastic syndrome: , 2006, Cancer.

[44]  W. Hiddemann,et al.  Determination of relapse risk based on assessment of minimal residual disease during complete remission by multiparameter flow cytometry in unselected patients with acute myeloid leukemia. , 2004, Blood.

[45]  G. Schuurhuis,et al.  MRD parameters using immunophenotypic detection methods are highly reliable in predicting survival in acute myeloid leukaemia , 2004, Leukemia.

[46]  C. Bloomfield,et al.  Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[47]  I. Bernstein,et al.  Immunophenotypic evidence of leukemia after induction therapy predicts relapse: results from a prospective Children's Cancer Group study of 252 patients with acute myeloid leukemia. , 2002, Blood.

[48]  A. Órfão,et al.  Early immunophenotypical evaluation of minimal residual disease in acute myeloid leukemia identifies different patient risk groups and may contribute to postinduction treatment stratification. , 2001, Blood.

[49]  D. Grimwade,et al.  The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial. , 2001, Blood.